Quantifying Cancer Absolute Risk and Cancer Mortality in the Presence of Competing Events after a Myotonic Dystrophy Diagnosis

• Shahinaz M. Gadalla,

  Affiliation Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Ruth M. Pfeiffer,

  Affiliation Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Sigurdur Y. Kristinsson,

  Affiliations Department of Medicine, Division of Hematology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden, Faculty of Medicine, University of Iceland and Department of Hematology, Landspitali National University Hospital, Reykjavik, Iceland

  ⨯
• Magnus Björkholm,

  Affiliation Department of Medicine, Division of Hematology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden

  ⨯
• James E. Hilbert,

  Affiliation Department of Neurology, Neuromuscular Disease Center, University of Rochester Medical Center, Rochester, New York, United States of America

  ⨯
• Richard T. Moxley III,

  Affiliation Department of Neurology, Neuromuscular Disease Center, University of Rochester Medical Center, Rochester, New York, United States of America

  ⨯
• Ola Landgren,

  Affiliation Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Mark H. Greene

  * E-mail: greenem@mail.nih.gov

  Affiliation Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯